The Failure Of Biosimilars In The US: ‘Headline’ News

 
• By Michael McCaughan

A Washington Post article on price hikes for Abbvie’s Humira highlights patent ‘thickets’ and anti-biosimilar strategies. But the lack of understanding of the basic concepts of the biosimilar system are a much bigger warning sign about the viability of the pathway.

two crossed syringe and question mark on white background
The Washington Post doesn't seem to appreciate the difference between biosimilars and generics, underscore the challenges facing the pathway in general.

More from Biosimilars

More from Biosimilars & Generics